2561 Share Price Performance
HK$35.66
-33.14 (-48.17%)
Price HK$35.66
Share Pricen/a
Here's Why We're Not At All Concerned With VISEN Pharmaceuticals' (HKG:2561) Cash Burn Situation
Nov 25
VISEN Pharmaceuticals Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
2561 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
VISEN Pharmaceuticals Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -2.06
- 100.00%
- -25,777.76%
- 0%
About 2561
- Founded
- 2018
- Employees
- 54
- CEO
- WebsiteView website
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare. VISEN Pharmaceuticals was incorporated in 2018 and is headquartered in Suzhou, China.
